Single Center Registration Study on HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer.
This study is a single center, non-interference, retrospective registration study: HER2 testing and disease information collection were conducted on patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023. Statistical analysis was conducted on the collected information to analyze the expression of HER2 in Chinese prostate patients and the correlation between HER2 and disease type.
• 1\. Prostate cancer patients confirmed by histopathology in our hospital from January 2018 to July 2023;
• 2\. Men aged ≥ 18 years old;
• 3\. The expected survival time is greater than 12 weeks;
• 4\. The KPS functional status score is greater than 60, and the ECOG status score is 0-2 points;
• 5\. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.